arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Alkermes plc.

ALKS
$49.18 ▲ +0.77 (+1.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

Alkermes plc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $8.1B
Dividend Yield
Revenue Growth -5.2%
Op. Margin 17.2%
ROIC 11.6%
FCF / Share $2.92
Trailing P/E 33.5x
Price / Book 4.5x
FCF Yield 5.9%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.48B
↓ -5.2%
Net Income Profit after all expenses
$241.66M
↓ -34.2%
Operating Margin Operating profit as % of sales
17.2%
↓ -36.3% 71th
FCF / Share Free cash flow per share
$2.92
↑ +18.9%
Long-Term Debt Long-term obligations
$287.73M
↓ -0.9%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
80
Returns
77
Cash Quality
86

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters